^
Association details:
Biomarker:No biomarker
Cancer:Renal Cell Carcinoma
Drug:Krabeva (bevacizumab biosimilar) (VEGF-A inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Title:

Biocon Biologics and Viatris Receive European Commission Approval for Biosimilar Bevacizumab

Published date:
04/26/2021
Excerpt:
...Biocon Biologics Ltd...has announced that Abevmy® 100 & 400 mg, a biosimilar of Bevacizumab co-developed with Viatris Inc. (NASDAQ: VTRS) has received marketing authorization approval from the European Commission...Abevmy® 100 & 400 mg, a biosimilar Bevacizumab, is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer, non-small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen.